Insights

Strategic Acquisition Interius BioTherapeutics has been acquired by Kite Pharma (a Gilead company) for 350 million, signaling strong investor confidence in in vivo CAR T therapies and potential cross-sell opportunities with Kite's global sales network.

In Vivo CAR T Focus The company concentrates on in vivo CAR T and autologous CAR cell generation inside patients, presenting a niche capability that can complement existing off-the-shelf or ex vivo platforms in partner portfolios.

European Expansion Regulatory approval to expand Phase 1 INT2104 trials into Europe indicates readiness for international clinical collaborations, licensing discussions, and regional commercialization partnerships.

Early-stage Funding Signals Reported revenue in the range of 10–25 million alongside growth initiatives suggests opportunity for tiered collaboration discussions, including sponsored research, co-development, or strategic investments.

Talent and IP Momentum Recent hires and a focus on lentiviral delivery technology imply a developing IP and expert execution capability, which could be leveraged in joint development programs or technology licensing conversations with larger biopharma partners.

Interius BioTherapeutics Tech Stack

Interius BioTherapeutics uses 8 technology products and services including WordPress, Shopify, Microsoft Excel, and more. Explore Interius BioTherapeutics's tech stack below.

  • WordPress
    Content Management System
  • Shopify
    E-commerce
  • Microsoft Excel
    Editors
  • jQuery
    Javascript Libraries
  • Microsoft Office
    Office Suites
  • PHP
    Programming Languages
  • Lua
    Programming Languages
  • X-Content-Type-Options
    Web & Portal Technology

Media & News

Interius BioTherapeutics's Email Address Formats

Interius BioTherapeutics uses at least 1 format(s):
Interius BioTherapeutics Email FormatsExamplePercentage
First.Last@interiusbio.comJohn.Doe@interiusbio.com
98%
First.Middle@interiusbio.comJohn.Michael@interiusbio.com
2%

Frequently Asked Questions

What is Interius BioTherapeutics's official website and social media links?

Minus sign iconPlus sign icon
Interius BioTherapeutics's official website is interiusbio.com and has social profiles on LinkedInCrunchbase.

How much revenue does Interius BioTherapeutics generate?

Minus sign iconPlus sign icon
As of July 2026, Interius BioTherapeutics's annual revenue is estimated to be $10M - $25M.

What is Interius BioTherapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Interius BioTherapeutics's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Interius BioTherapeutics have currently?

Minus sign iconPlus sign icon
As of July 2026, Interius BioTherapeutics has approximately 19 employees across 1 continents, including North America. Key team members include Senior Director, Analytical Development: J. R.Associate Manager Project Management: K. R.Office Manager: K. S.. Explore Interius BioTherapeutics's employee directory with LeadIQ.

What industry does Interius BioTherapeutics belong to?

Minus sign iconPlus sign icon
Interius BioTherapeutics operates in the Biotechnology Research industry.

What technology does Interius BioTherapeutics use?

Minus sign iconPlus sign icon
Interius BioTherapeutics's tech stack includes WordPressShopifyMicrosoft ExceljQueryMicrosoft OfficePHPLuaX-Content-Type-Options.

What is Interius BioTherapeutics's email format?

Minus sign iconPlus sign icon
Interius BioTherapeutics's email format typically follows the pattern of First.Last@interiusbio.com. Find more Interius BioTherapeutics email formats with LeadIQ.

How much funding has Interius BioTherapeutics raised to date?

Minus sign iconPlus sign icon
As of July 2026, Interius BioTherapeutics has raised $176M in funding. The last funding round occurred on Jan 01, 2025 for $22M.
Interius BioTherapeutics logo

Interius BioTherapeutics

Biotechnology ResearchPennsylvania, United States11-50 Employees

Interius BioTherapeutics is a biotechnology research company based in Philadelphia, Pennsylvania. It develops cell-therapy approaches that aim to generate CAR T and CAR NK cells inside patients’ bodies, with the goal of delivering therapies that could be faster, potentially less expensive, and more widely accessible than current CAR T treatments. The organization is now part of Kite, a Gilead company focused on advancing cures with cell therapy. In recent years, Interius has pursued clinical development activities, including regulatory approval to expand a Phase 1 trial of INT2104 into Europe, and it has extended its European footprint. As a small to mid-sized company, it operates within the biotechnology research space and concentrates on in vivo strategies for CAR-based therapies.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $176M

    Interius BioTherapeutics has raised a total of $176M of funding over 5 rounds. Their latest funding round was raised on Jan 01, 2025 in the amount of $22Mas a series_unknown.

  • $10M - $25M

    Interius BioTherapeutics's revenue is estimated to be in the range of $10M - $25M

Section iconFunding & Financials

  • $176M

    Interius BioTherapeutics has raised a total of $176M of funding over 5 rounds. Their latest funding round was raised on Jan 01, 2025 in the amount of $22Mas a series_unknown.

  • $10M - $25M

    Interius BioTherapeutics's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.